News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Ark Therapeutics to License Out Heart Attack Risk Kit Marketing
October 8, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Oct 8 (Reuters) - Ark Therapeutics (AKT.L: Quote, Profile, Research) said on Monday it was to license out marketing rights for its Ox-LDL heart attack risk test kit to UK-based diagnostics company Lab21.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
MORE ON THIS TOPIC
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
·
1 min read
·
Jennifer Smith-Parker
Alzheimer’s disease
Korsana Joins Alzheimer’s Amyloid Arena With $150M Debut, Next-Gen Antibody
February 18, 2026
·
2 min read
·
Tristan Manalac
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Rare diseases
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
February 18, 2026
·
3 min read
·
Annalee Armstrong
